Zealand Pharma Statistics
Zealand Pharma (22Z) Stock Statistics & Valuation Metrics
Total Valuation
Zealand Pharma has a market cap or net worth of EUR 2.07B. The enterprise value is EUR 6.45B.
- Market Cap
- EUR 2.07B
- Enterprise Value
- EUR 6.45B
Share Statistics
Zealand Pharma has 71,610,010 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 71,610,010
- Owned by Insiders
- ―
- Owned by Institutions
- 24.85%
Financial Efficiency
Zealand Pharma’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -13.89%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.11
- Return on Invested Capital (ROIC)
- -13.89%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 108.46K
- Profits Per Employee
- -1.87M
- Employee Count
- 578
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.74
Valuation Ratios
The current PE Ratio of Zealand Pharma is -21.74. Zealand Pharma’s PEG ratio is 3.46.
- PE Ratio
- -21.74
- PS Ratio
- 465.35
- PB Ratio
- 3.10
- Price to FCF
- -21.13
- Price to Operating Cash Flow
- -21.34
- PEG Ratio
- 3.46
Income Statement
In the last 12 months, Zealand Pharma had revenue of 62.69M and earned -1.08B in profits. Earnings per share was -16.24.
- Revenue
- 62.69M
- Gross Profit
- 54.82M
- Operating Income
- -1.27B
- Pretax Income
- -1.08B
- Net Income
- -1.08B
- EBITDA
- -1.02B
- Earnings Per Share (EPS)
- -16.24
Cash Flow
In the last 12 months, operating cash flow was -1.21B and capital expenditures -18.38M, giving a free cash flow of -1.23B billion.
- Operating Cash Flow
- -1.21B
- Free Cash Flow
- -1.23B
- Free Cash Flow per Share
- -17.37
Dividends & Yields
Zealand Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.73%
- Earnings Yield
- -4.60%
Stock Price Statistics
- Beta
- 1.48
- 52-Week Price Change
- -44.98%
- 50-Day Moving Average
- 34.67
- 200-Day Moving Average
- 40.35
- Relative Strength Index (RSI)
- 41.30
- Average Volume (3m)
- 369
Important Dates
Zealand Pharma upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Zealand Pharma as a current ratio of 21.14, with Debt / Equity ratio of 4.55%
- Current Ratio
- 21.14
- Quick Ratio
- 21.11
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.09
- Interest Coverage Ratio
- -31.11
Taxes
In the past 12 months, Zealand Pharma has paid -4.62M in taxes.
- Income Tax
- -4.62M
- Effective Tax Rate
- 0.00
Enterprise Valuation
Zealand Pharma EV to EBITDA ratio is -22.99, with an EV/FCF ratio of -20.82.
- EV to Sales
- 458.50
- EV to EBITDA
- -22.99
- EV to Free Cash Flow
- -20.82
- EV to Operating Cash Flow
- -21.14
Balance Sheet
Zealand Pharma has EUR 8.54B in cash and marketable securities with EUR 394.64M in debt, giving a net cash position of EUR 8.15B billion.
- Cash & Marketable Securities
- EUR 8.54B
- Total Debt
- EUR 394.64M
- Net Cash
- EUR 8.15B
- Net Cash Per Share
- EUR 113.81
- Tangible Book Value Per Share
- EUR 117.69
Margins
Gross margin is 93.39%, with operating margin of -2555.76%, and net profit margin of -2128.64%.
- Gross Margin
- 93.39%
- Operating Margin
- -2555.76%
- Pretax Margin
- -2136.97%
- Net Profit Margin
- -2128.64%
- EBITDA Margin
- -1994.72%
- EBIT Margin
- -2045.23%
Analyst Forecast
The average price target for Zealand Pharma is EUR 51.18, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 51.18
- Price Target Upside
- 65.73% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -49.11%
- EPS Growth Forecast
- -59.03%
